Press Releases

October 26, 2022 at 4:30 PM EDT

Summary Toggle Arcturus Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 9, 2022

SAN DIEGO --(BUSINESS WIRE)--Oct. 26, 2022-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and

PDF Version
September 27, 2022 at 6:00 PM EDT

Summary Toggle Arcturus Therapeutics to Attend the Following Investor Conferences

SAN DIEGO --(BUSINESS WIRE)--Sep. 27, 2022-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global, late-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare

PDF Version
September 1, 2022 at 4:00 PM EDT

Summary Toggle Arcturus Therapeutics to Attend the Following Investor Conferences

SAN DIEGO --(BUSINESS WIRE)--Sep. 1, 2022-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global, late-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare

PDF Version
August 31, 2022 at 4:00 PM EDT

Summary Toggle Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of Self-amplifying mRNA Vaccine for Rapid Pandemic Influenza Response

Arcturus will expand its current influenza vaccine program to include development of a pandemic influenza vaccine based on its proprietary self-amplifying mRNA platform with the support of the Biomedical Advanced Research and Development Authority $63.2 Million base award to fund development from

PDF Version
August 18, 2022 at 8:00 AM EDT

Summary Toggle Arcturus Reports Durability Data Against Omicron Variants, Including BA.5, at Six-Month Timepoint Following Booster with ARCT-154 COVID-19 Vaccine

New clinical data demonstrate high and sustained geometric mean fold rises (GMFR) in neutralizing antibodies against all evaluated Omicron variants Six months after booster dose of ARCT-154: BA.1: GMFR = 22 to 52; Titer = 674 to 1524 BA.2: GMFR = 25 to 55; Titer = 777 to 1713 BA.5: GMFR = 9 to

PDF Version
August 9, 2022 at 4:00 PM EDT

Summary Toggle Arcturus Therapeutics Announces Second Quarter 2022 Financial Update and Pipeline Progress

New ARCT-154 clinical booster data demonstrate promising durability; 44- and 39-fold increases in neutralizing antibody response against Omicron BA.1 and BA.2 at Day 91 New cold chain data for Arcturus’ lyophilized vaccine platform shows favorable stability, shipping, and storage advantages

PDF Version
August 1, 2022 at 4:00 PM EDT

Summary Toggle Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022

SAN DIEGO --(BUSINESS WIRE)--Aug. 1, 2022-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and

PDF Version
June 21, 2022 at 8:00 PM EDT

Summary Toggle Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO --(BUSINESS WIRE)--Jun. 21, 2022-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and

PDF Version
May 20, 2022 at 8:00 PM EDT

Summary Toggle Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO --(BUSINESS WIRE)--May 20, 2022-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and

PDF Version
May 9, 2022 at 4:00 PM EDT

Summary Toggle Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress

ARCT-154 booster data show 54- and 46-fold increases in neutralizing antibody response against Omicron BA.1 and BA.2 Investor conference call at 4:30 p.m. ET today SAN DIEGO --(BUSINESS WIRE)--May 9, 2022-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global

PDF Version